Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 100, Topic 4
In Progress

Supportive Care and Prevention of Complications in Open Fracture Management

Lesson Progress
0% Complete
Supportive Care in Open Fracture Management

Supportive Care in Open Fracture Management

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Learning Objective

Recommend appropriate supportive care and monitoring to manage complications associated with open fracture treatment.

1. Respiratory and Hemodynamic Support

Open fractures often occur in the context of polytrauma, necessitating immediate ventilatory support and hemodynamic stabilization to prevent secondary insults from hypoxia and hypoperfusion.

A. Indications for Mechanical Ventilation

  • Airway Compromise: Obstruction from bleeding, edema, or direct facial trauma.
  • Neurologic Impairment: Glasgow Coma Scale (GCS) ≤8 in the setting of traumatic brain injury (TBI).
  • Thoracic Injury: Flail chest, multiple rib fractures, or severe pulmonary contusion leading to respiratory failure.
  • Spinal Cord Injury: High cervical or thoracic injuries causing diaphragmatic or intercostal muscle dysfunction.

B. Ventilator and Resuscitation Strategies

  • Ventilator Management: Employ lung-protective strategies with tidal volumes of 6–8 mL/kg of predicted body weight and maintain plateau pressures ≤30 cm H₂O. Titrate PEEP to optimize oxygenation while preserving hemodynamics.
  • Hemodynamic Resuscitation: Initiate damage-control resuscitation with a balanced transfusion ratio (1:1:1 of packed red blood cells, fresh frozen plasma, and platelets). In bleeding trauma without TBI, permissive hypotension (systolic BP 80–90 mm Hg) is acceptable until hemorrhage is controlled.
  • Pharmacologic Adjuncts: Administer tranexamic acid (1 g IV over 10 min, then 1 g over 8 h) if within 3 hours of injury. Use balanced crystalloids and add vasopressors (norepinephrine) as needed to maintain a mean arterial pressure (MAP) ≥65 mm Hg after bleeding is controlled.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearls

Parallel Processes: Initiate resuscitation and preparations for intubation simultaneously. Delaying definitive airway management in a hypoxemic, unstable patient significantly increases the risk of peri-intubation cardiac arrest.

Monitor for Compartment Syndrome: Be vigilant for abdominal compartment syndrome, especially after high-volume fluid resuscitation, as it can precipitate multi-organ failure.

2. Pharmacotherapy Considerations

Prophylactic and preventative pharmacologic strategies are critical to reducing common ICU-related complications in immobilized trauma patients.

A. Venous Thromboembolism (VTE) Prophylaxis

Trauma patients face a high risk of VTE due to a triad of immobilization, endothelial injury, and a systemic hypercoagulable state. A dual approach using mechanical and pharmacologic methods is recommended.

Pharmacologic VTE Prophylaxis Agents
Agent Standard Dose Key Considerations
Mechanical Prophylaxis Intermittent pneumatic compression (IPC) devices Start immediately upon admission unless contraindicated by the fracture site or severe peripheral vascular disease.
Low-Molecular-Weight Heparin (LMWH) Enoxaparin 30 mg SC every 12 hours Dose-adjust to 30 mg SC daily if CrCl <30 mL/min. Consider anti-Xa monitoring (target peak 0.2–0.4 IU/mL) in obesity or renal impairment.
Unfractionated Heparin (UFH) 5,000 units SC every 8 hours Preferred agent for patients with severe renal dysfunction (CrCl <30 mL/min) or very high bleeding risk due to its short half-life.

Contraindications to pharmacologic prophylaxis include: active bleeding, severe thrombocytopenia (platelets <50,000/mm³), or uncontrolled coagulopathy.

Note IconA document icon, representing an editor’s note. Editor’s Note: Guideline Consultation

The optimal VTE prophylaxis strategy in complex trauma can be nuanced. Always consult the most recent American College of Chest Physicians (ACCP) or institutional guidelines for specific recommendations based on bleeding risk, fracture pattern, and patient comorbidities.

B. Stress Ulcer Prophylaxis (SUP)

SUP is indicated for patients with major risk factors for clinically significant gastrointestinal bleeding.

  • Indications: Mechanical ventilation for >48 hours, or coagulopathy (INR >1.5 or platelets <50,000/mm³).
  • Agents: Proton-pump inhibitors (e.g., pantoprazole 40 mg IV daily) or H₂-receptor antagonists (e.g., famotidine 20 mg IV every 12 hours).
  • Duration: Continue only while risk factors are present. Discontinue upon ventilator liberation or resolution of coagulopathy to minimize adverse effects like C. difficile infection and pneumonia.

C. Central Line–Associated Bloodstream Infection (CLABSI) Prevention

Strict adherence to insertion and maintenance bundles is the most effective strategy to prevent CLABSI.

CLABSI Prevention Bundle Flowchart A flowchart illustrating the five core components of the CLABSI prevention bundle: Hand Hygiene, Chlorhexidine Skin Prep, Optimal Site Selection, Daily Review of Necessity, and Proper Dressing Care. Core Components of the CLABSI Prevention Bundle 1. Hand Hygiene & Maximal Barrier Precautions 2. Chlorhexidine Skin Antisepsis 3. Optimal Site Selection (Subclavian > IJ) 4. Daily Review of Catheter Necessity & Prompt Removal 5. Aseptic Dressing Care (CHG or transparent)
Figure 1: The CLABSI Prevention Bundle. A systematic, evidence-based approach to central line insertion and maintenance is paramount to reducing infection rates.

D. Management of Antibiotic-Related Complications

Prolonged courses of broad-spectrum antibiotics, common in open fracture management, necessitate surveillance for drug-related adverse events.

1. Clostridioides difficile Infection (CDI)

Antibiotic-induced dysbiosis allows C. difficile to proliferate and release toxins, causing colitis. Risk is increased by broad-spectrum agents, prolonged therapy, and PPI use.

  • Treatment: Oral vancomycin (125 mg QID) or fidaxomicin (200 mg BID) for 10 days. Consider adding bezlotoxumab (10 mg/kg IV single dose) for patients at high risk of recurrence.
  • Prevention: Focus on antibiotic stewardship by limiting therapy duration, de-escalating when possible, and reassessing the need for PPIs daily.

2. Organ Dysfunction

Monitoring for Antibiotic-Induced Organ Dysfunction
Toxicity Common Culprits Monitoring & Prevention
Nephrotoxicity Aminoglycosides, Vancomycin Monitor daily serum creatinine and hourly urine output. Target vancomycin troughs 15–20 mg/L. Use once-daily aminoglycoside dosing and avoid concomitant nephrotoxins.
Hepatotoxicity Linezolid, High-dose β-lactams Monitor AST/ALT levels twice weekly during therapy. Adjust doses in pre-existing hepatic impairment and monitor drug levels if available.

3. Multidisciplinary Goals of Care and Operative Timing

Collaborative, patient-centered planning is essential to ensure the optimal timing of surgical interventions and align the overall plan of care with patient and family values.

A. The Multidisciplinary Team

Daily rounds should ideally include representatives from trauma surgery, orthopedics, anesthesia, critical care, infectious diseases, pharmacy, and rehabilitation services to create a cohesive daily plan.

B. Operative Timing

  • Initial Debridement: The first dose of antibiotics should be given within 1 hour of injury. Surgical irrigation and debridement should occur within 24 hours, once the patient is physiologically stabilized.
  • Definitive Coverage: Definitive soft tissue coverage is ideally performed within 72 hours to reduce infection rates and improve flap viability.
  • Damage Control Orthopedics: For hemodynamically unstable patients, external fixation is used as a temporary bridge to stabilize the fracture, allowing for physiologic recovery before definitive internal fixation.

C. Communication

Proactive communication is key. Conduct a formal family meeting by the second ICU day to discuss the overall prognosis, surgical risks, and the spectrum of expected outcomes, including the possibility of limb salvage versus amputation. All goals of care discussions and advance directives must be clearly documented.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: “Fix and Flap” vs. Physiologic State

The traditional “fix and flap” timeline is a guideline, not a mandate. The patient’s physiologic state—not the clock—is the ultimate determinant of operative timing. Proceeding with major surgery on an unstable, acidotic, or hypothermic patient significantly increases morbidity and mortality. Prioritize resuscitation first.

4. Monitoring and Quality Metrics

Systematic surveillance and tracking of stewardship metrics are essential for driving continuous quality improvement in the supportive care of open fracture patients.

  • VTE Surveillance: Perform screening duplex ultrasonography in high-risk, immobile patients, even if on prophylaxis, as the incidence of occult DVT remains high.
  • CLABSI Tracking: Monitor infection rates per 1,000 catheter-days according to CDC/NHSN definitions to benchmark performance and identify trends.
  • Antibiotic Stewardship Metrics: Track days of therapy (DOT), time to appropriate de-escalation, and institutional incidence of C. difficile. Implement regular audits with direct feedback to the ICU team.
  • Adverse Event Tracking: Systematically monitor for and report antibiotic-related complications such as nephrotoxicity, hepatotoxicity, and severe allergic reactions.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: The Power of Dashboards

Integrating key quality metrics into a real-time electronic dashboard can significantly enhance decision support at the bedside. Visualizing trends in VTE rates, CLABSI incidence, and antibiotic utilization allows teams to quickly identify deviations from best practice and implement corrective actions.

References

  1. Ramesh GH, Kumar S, Kumar A, et al. Damage control resuscitation and hemodynamic stabilization in trauma. Int J Emerg Med. 2019;12:38.
  2. Zalavras CG. Prevention of infection in open fractures. Infect Dis Clin North Am. 2017;31(2):339–352.
  3. Kim YJ, Kim JS, Park YS, et al. Central line–associated bloodstream infections in the ICU: efficacy of a care bundle. Am J Infect Control. 2016;44(9):e189–e193.
  4. Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med. 2004;32(10):2014–2020.
  5. Appelbaum RD, Como JJ, Claridge JA, et al. Antibiotic prophylaxis in injury: an American Association for the Surgery of Trauma consensus update of the Eastern Association for the Surgery of Trauma’s 2012 guidelines. Trauma Surg Acute Care Open. 2024;9(1):e001304.